(b) ADDITIONAL REPORTING.—In the first threat-based review submitted after the date of enactment of this Act pursuant to paragraph (2) of section 319F–2(a) of the Public Health Service Act (42 U.S.C. 247d–6b(a)), as amended by subsection (a), the Secretary shall include a description of the processes and procedures through which the Director of the Strategic National Stockpile and the Director of the Biomedical Advanced Research and Develop- ment Authority coordinate with respect to countermeasures and products procured under such section 319F–2(a), including such processes and procedures in place to ensure countermeasures and products under consideration for procurement pursuant to such section 319F–2(a) receive the same consideration regardless of whether such countermeasures or products receive or had received funding under section 319L of the Public Health Service Act (42 U.S.C. 247d–7e), and whether such countermeasures and products are the most appropriate to meet the emergency health security needs of the United States. 

(c) AUTHORIZATION OF APPROPRIATIONS, STRATEGIC NATIONAL STOCKPILE.—Section 319F–2(f)(1) (42 U.S.C. 247d–6b(f)(1)) is amended by striking ‘‘$533,800,000 for each of fiscal years 2014 through 2018’’ and inserting ‘‘$610,000,000 for each of fiscal years 2019 through 2023, to remain available until expended’’. 

(including additions, modifications, and replenish- ments) in the stockpile, and how such expenditures relate to the ability of the stockpile to meet emergency health security needs; 

‘‘(vii) an assessment of the extent to which addi- tions, modifications, and replenishments reviewed under paragraph (2) align with previous relevant reports or reviews by the Secretary or the Comptroller General; 

‘‘(viii) with respect to any change in the Federal organizational management of the stockpile, an assess- ment and comparison of the processes affected by such change, including planning for potential counter- measure deployment, distribution, or dispensing capabilities and processes related to procurement decisions, use of stockpiled countermeasures, and use of resources for such activities; and 

‘‘(ix) an assessment of whether the processes and procedures described by the Secretary pursuant to sec- tion 403(b) of the Pandemic and All-Hazards Prepared- ness and Advancing Innovation Act of 2019 are suffi- cient to ensure countermeasures and products under consideration for procurement pursuant to subsection (a) receive the same consideration regardless of whether such countermeasures and products receive or had received funding under section 319L, including with respect to whether such countermeasures and products are most appropriate to meet the emergency health security needs of the United States. 

‘‘(B) SUBMISSION.—Not later than 6 months after com- pleting a classified version of the review under subpara- graph (A), the Comptroller General shall submit an unclassified version of the review to the congressional committees of jurisdiction.’’. 

Deadline. 

